Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Coordination and Support Action · Running

TransBioNet Accelerating Biomedical Translation through a European Network of Knowledge Valorisation Intermediaries

Coordinator
Associação Accelbio, Portugal
Runs
1 September 2026 to 31 August 2029
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
7 organisations in 6 countries
Type
Coordination and Support Action
Grant agreement
101291691

What the project is doing

In the project's own words, from its summary on CORDIS.

TransBioNet will establish the first pan-European network of knowledge valorisation intermediaries fully dedicated to drug discovery and biomedical innovation. Despite Europe’s world-class science, promising discoveries often fail to reach patients due to fragmented support, under-recognised intermediaries, and limited cross-border collaborations. TransBioNet addresses this gap by connecting regional clusters, pan-European infrastructures, and accelerators into a coherent ecosystem that equips intermediaries with harmonised tools, training, and services.

The project will deliver three flagship resources: (i) the TransBioNet Digital Platform, a central hub integrating the Infrastructure Atlas, matchmaking tools, and training modules; (ii) a Valorisation Assessment Toolkit, providing standardised TRL/IRL evaluations embedding regulatory, IP, and market dimensions; and (iii) the TransBioNet Charter, a policy framework to ensure recognition of intermediaries across EU and national innovation strategies.

Two Open Calls will support 12 early-stage drug discovery projects with mentoring, bootcamps, and access to infrastructures, creating tangible case studies of valorisation in practice. Through training programmes, secondments, and a Community of Practice, the project will build a new generation of skilled intermediaries able to de-risk biomedical projects, improve reproducibility, and accelerate translation. By lowering attrition rates and increasing investment readiness, TransBioNet will strengthen Europe’s competitiveness in drug discovery while ensuring inclusive participation of less-resourced regions.

The project directly advances ERA Action 7 on Knowledge Valorisation, reinforcing open science, responsible research assessment, and cross-border collaboration. By its conclusion, TransBioNet will deliver a recognised European reference point for biomedical valorisation, ensuring that high-quality science translates into innovative therapies, jobs & societal impact.

Who is involved

OrganisationCityCountryRole
Associação AccelbioCantanhedePortugalCoordinator
Biotehnologichen I Zdraven KlasterSofiaBulgariaParticipant
Eit Health Innostars eVMunchenGermanyParticipant
Foreningen Danish Life Science ClusterKobenhavnDenmarkParticipant
Asociacija LithuaniabioVilniusLithuaniaParticipant
Eatris EricAmsterdamNetherlandsParticipant
Biocant Park, S.a.CantanhedePortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS